Clinical Trials Browser

Recurrence × Methylprednisolone Acetate × Plasma cell × Clear all

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Phase 2 Terminated

Multiple Myeloma, Recurrence